If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> GASTROENTEROLOGY<br /> EMJ Gastroenterol. 2017 Suppl 8 • europeanmedical-journal.com<br /> INSIDE<br /> Changing the Game in<br /> Ulcerative Colitis: The Impact<br /> of Gut-Selective Therapy<br /> Targeting Disease Progression<br /> in Crohn’s Disease: Fighting<br /> an Unrelenting Enemy<br /> CHANGING THE GAME IN ULCERATIVE COLITIS:<br /> THE IMPACT OF GUT-SELECTIVE THERAPY<br /> This satellite symposium took place on 17th February 2017<br /> as part of the European Crohn’s and Colitis Organisation<br /> (ECCO) Congress in Barcelona, Spain<br /> Chairperson<br /> Jean-Frédéric Colombel1<br /> Speakers<br /> Jean-Frédéric Colombel,1 Brian G. Feagan,2 Stefan Schreiber3<br /> 1. Icahn School of Medicine at Mount Sinai, New York City, New York, USA<br /> 2. Western University, London, Ontario, Canada<br /> 3. Clinic of Internal Medicine I, Christian-Albrechts-University<a title="EMJ Gastroenterol. 2017 Suppl 8 page 1" href="http://viewer.zmags.com/publication/095c63a3?page=1"> GASTROENTEROLOGY EMJ Gastroenterol. 2017 Suppl 8 </a> <a title="EMJ Gastroenterol. 2017 Suppl 8 page 2" href="http://viewer.zmags.com/publication/095c63a3?page=2"> CHANGING THE GAME IN ULCERATIVE COLITIS: THE</a> <a title="EMJ Gastroenterol. 2017 Suppl 8 page 3" href="http://viewer.zmags.com/publication/095c63a3?page=3"> Prof Schreiber reviewed vedolizumab, a gut-select</a> <a title="EMJ Gastroenterol. 2017 Suppl 8 page 4" href="http://viewer.zmags.com/publication/095c63a3?page=4"> Disease location at diagnosis Proctitis </a> <a title="EMJ Gastroenterol. 2017 Suppl 8 page 5" href="http://viewer.zmags.com/publication/095c63a3?page=5"> used in conjunction with histology for an assessm</a> <a title="EMJ Gastroenterol. 2017 Suppl 8 page 6" href="http://viewer.zmags.com/publication/095c63a3?page=6"> induction. However, many clinicians are now movin</a> <a title="EMJ Gastroenterol. 2017 Suppl 8 page 7" href="http://viewer.zmags.com/publication/095c63a3?page=7"> UC is a ‘patchy’ disease, making it possible to t</a> <a title="EMJ Gastroenterol. 2017 Suppl 8 page 8" href="http://viewer.zmags.com/publication/095c63a3?page=8"> Induction Mesalazine or index steroid course St</a> <a title="EMJ Gastroenterol. 2017 Suppl 8 page 9" href="http://viewer.zmags.com/publication/095c63a3?page=9"> REFERENCES 1. “Estimated Exposure and </a> <a title="EMJ Gastroenterol. 2017 Suppl 8 page 10" href="http://viewer.zmags.com/publication/095c63a3?page=10"> (Supplementary material). 40. Schreiber S et al. </a> <a title="EMJ Gastroenterol. 2017 Suppl 8 page 11" href="http://viewer.zmags.com/publication/095c63a3?page=11"> TARGETING DISEASE PROGRESSION IN CROHN’S DISEAS</a> <a title="EMJ Gastroenterol. 2017 Suppl 8 page 12" href="http://viewer.zmags.com/publication/095c63a3?page=12"> Slowing Progression of Crohn’s Disease: De</a> <a title="EMJ Gastroenterol. 2017 Suppl 8 page 13" href="http://viewer.zmags.com/publication/095c63a3?page=13"> An endoscopy sub-study of the ACCENT I trial (the</a> <a title="EMJ Gastroenterol. 2017 Suppl 8 page 14" href="http://viewer.zmags.com/publication/095c63a3?page=14"> Such concerns emphasise the importance of de</a> <a title="EMJ Gastroenterol. 2017 Suppl 8 page 15" href="http://viewer.zmags.com/publication/095c63a3?page=15"> A systematic meta-analysis presented at ECCO</a> <a title="EMJ Gastroenterol. 2017 Suppl 8 page 16" href="http://viewer.zmags.com/publication/095c63a3?page=16"> Vedolizumab real-world mucosal healing data 100 </a> <a title="EMJ Gastroenterol. 2017 Suppl 8 page 17" href="http://viewer.zmags.com/publication/095c63a3?page=17"> Product Characteristics. 2017. Available at: </a> <a title="EMJ Gastroenterol. 2017 Suppl 8 page 18" href="http://viewer.zmags.com/publication/095c63a3?page=18"> 43. Alam N et al. Comparative effectiveness analy</a>